Improved detection and management of advanced HIV disease through a community adult TB-contact tracing intervention with same-day provision of the WHO-recommended package of care including ART initiation in a rural district of Mozambique.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
08 2021
Historique:
revised: 02 06 2021
received: 15 12 2020
accepted: 05 07 2021
entrez: 4 8 2021
pubmed: 5 8 2021
medline: 27 10 2021
Statut: ppublish

Résumé

AIDS-mortality remains unacceptably high in sub-Saharan Africa, largely driven by advanced HIV disease (AHD). We nested a study in an existing tuberculosis (TB) contact-tracing intervention (Xpatial-TB). The aim was to assess the burden of AHD among high-risk people living with HIV (PLHIV) identified and to evaluate the provision of the WHO-recommended package of care to this population. All PLHIV ≥14 years old identified between June and December 2018 in Manhiça District by Xpatial-TB were offered to participate in the study if ART naïve or had suboptimal ART adherence. Consenting individuals were screened for AHD. Patients with AHD (CD4 < 200 cells/μL or WHO stage 3 or 4) were offered a package of interventions in a single visit, including testing for cryptococcal antigen (CrAg) and TB-lipoarabinomannan (TB-LAM), prophylaxis and treatment for opportunistic infections, adherence support or accelerated ART initiation. We collected information on follow-up visits carried out under routine programmatic conditions for six months. A total of 2881 adults were identified in the Xpatial TB-contact intervention. Overall, 23% (673/2881) were HIV positive, including 351 TB index (64.2%) and 322 TB contacts (13.8%). Overall, 159/673 PLHIV (24%) were ART naïve or had suboptimal ART adherence, of whom 155 (97%, 124 TB index and 31 TB-contacts) consented to the study and were screened for AHD. Seventy percent of TB index-patients (87/124) and 16% of TB contacts (5/31) had CD4 < 200 cells/µL. Four (13%) of the TB contacts had TB, giving an overall AHD prevalence among TB contacts of 29% (9/31). Serum-CrAg was positive in 4.6% (4/87) of TB-index patients and in zero TB contacts. All ART naïve TB contacts without TB initiated ART within 48 hours of HIV diagnosis. Among TB cases, ART timing was tailored to the presence of TB and cryptococcosis. Six-month mortality was 21% among TB-index cases and zero in TB contacts. A TB contact-tracing outreach intervention identified undiagnosed HIV and AHD in TB patients and their contacts, undiagnosed cryptococcosis among TB patients, and resulted in an adequate provision of the WHO-recommended package of care in this rural Mozambican population. Same-day and accelerated ART initiation was feasible and safe in this population including among those with AHD.

Identifiants

pubmed: 34347366
doi: 10.1002/jia2.25775
pmc: PMC8336616
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25775

Informations de copyright

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.

Références

Clin Microbiol Rev. 2019 May 15;32(3):
pubmed: 31092508
J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):527-535
pubmed: 29771786
Curr Opin HIV AIDS. 2017 Mar;12(2):175-181
pubmed: 28079591
BMC Infect Dis. 2017 Dec 28;17(1):803
pubmed: 29282005
AIDS. 2019 Aug 1;33(10):1635-1644
pubmed: 31305331
Glob Health Action. 2014 Apr 08;7:23758
pubmed: 24717189
Sci Rep. 2017 Sep 7;7(1):10931
pubmed: 28883510
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):844-849
pubmed: 31439117
Am J Epidemiol. 2020 Aug 1;189(8):811-819
pubmed: 32219384
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S111-S117
pubmed: 29514238
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S118-S125
pubmed: 29514233
MMWR Morb Mortal Wkly Rep. 2018 Jun 15;67(23):663-667
pubmed: 29902168
Int J Mycobacteriol. 2018 Oct-Dec;7(4):395-396
pubmed: 30531043
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
PLoS One. 2018 Mar 2;13(3):e0193577
pubmed: 29499042
Open Forum Infect Dis. 2015 Nov 12;2(4):ofv173
pubmed: 26730391
Trop Med Int Health. 2007 Aug;12(8):929-35
pubmed: 17697087
AIDS. 2015 Sep 24;29(15):1987-2002
pubmed: 26266773
BMC Infect Dis. 2018 Mar 6;18(1):110
pubmed: 29510670
AIDS Res Ther. 2017 Jan 5;14(1):1
pubmed: 28086929
PLoS One. 2015 Mar 26;10(3):e0119822
pubmed: 25812013
BMC Med. 2015 Apr 02;13:70
pubmed: 25889688
J Fungi (Basel). 2018 Jun 23;4(3):
pubmed: 29937480
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):e69-76
pubmed: 25761234
Clin Infect Dis. 2017 Nov 13;65(11):1878-1883
pubmed: 29020319
J Clin Microbiol. 2016 Dec;54(12):3050-3055
pubmed: 27733636
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):189-94
pubmed: 23542636
BMC Infect Dis. 2018 Jul 4;18(1):299
pubmed: 29973140
Clin Infect Dis. 2010 Aug 15;51(4):448-55
pubmed: 20597693
PLoS One. 2020 Jan 7;15(1):e0226987
pubmed: 31910221
J Int AIDS Soc. 2018 Dec;21(12):e25210
pubmed: 30549245
J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):32-7
pubmed: 21654499
PLoS One. 2016 Oct 5;11(10):e0162085
pubmed: 27706150
Lancet HIV. 2020 Jul;7(7):e514-e520
pubmed: 32473102
PLoS One. 2017 Jun 16;12(6):e0179533
pubmed: 28622361
J Int AIDS Soc. 2016 Jan 12;19(1):20714
pubmed: 26765347
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
AIDS Res Treat. 2013;2013:941493
pubmed: 23956850
BMC Med. 2017 Mar 21;15(1):67
pubmed: 28320384
HIV Med. 2019 Mar;20 Suppl 1:3-11
pubmed: 30724450
Lancet HIV. 2018 Jan;5(1):e8-e9
pubmed: 29290227
AIDS Res Hum Retroviruses. 2015 Feb;31(2):198-207
pubmed: 25381732
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):605-611
pubmed: 30383587
J Int AIDS Soc. 2016 Mar 11;19(1):20672
pubmed: 26976377
AIDS Behav. 2015 Apr;19(4):666-78
pubmed: 25096897
Int J Tuberc Lung Dis. 2013 Apr;17(4):432-46
pubmed: 23485377
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e103-e105
pubmed: 30807483
PLoS One. 2020 Apr 3;15(4):e0230453
pubmed: 32243435
South Afr J HIV Med. 2015 Oct 08;16(1):346
pubmed: 29568579
AIDS. 2018 Sep 24;32(15):2141-2149
pubmed: 30005014
AIDS. 2018 Jan 2;32(1):17-23
pubmed: 29112073
PLoS One. 2016 Apr 13;11(4):e0153243
pubmed: 27073928
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):231-238
pubmed: 29509588
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S106-SS110
pubmed: 29514232
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e22-8
pubmed: 22627184
PLoS Med. 2019 Apr 5;16(4):e1002776
pubmed: 30951533
Trop Med Int Health. 2017 Jul;22(7):807-821
pubmed: 28449385
BMC Health Serv Res. 2018 Sep 14;18(1):711
pubmed: 30217152
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331035
PLoS Med. 2019 Apr 30;16(4):e1002792
pubmed: 31039161
PLoS One. 2016 Nov 9;11(11):e0166158
pubmed: 27829072
BMC Public Health. 2013 Feb 02;13:97
pubmed: 23374118
BMC Infect Dis. 2018 Oct 26;18(1):536
pubmed: 30367622
PLoS One. 2019 Apr 10;14(4):e0214739
pubmed: 30969987
PLoS One. 2018 Mar 2;13(3):e0192089
pubmed: 29499060
Curr HIV/AIDS Rep. 2015 Mar;12(1):107-16
pubmed: 25772785
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
Cochrane Database Syst Rev. 2018 Aug 29;8:CD004773
pubmed: 30156270
PLoS Med. 2019 Apr 30;16(4):e1002796
pubmed: 31039165
PLoS One. 2016 May 13;11(5):e0155256
pubmed: 27175484
J Int AIDS Soc. 2016 Aug 08;19(1):20888
pubmed: 27507249
Lancet HIV. 2019 Aug;6(8):e540-e551
pubmed: 31285181
Int J Tuberc Lung Dis. 2019 Feb 1;23(2):241-251
pubmed: 30808459
PLoS One. 2016 Aug 22;11(8):e0161469
pubmed: 27548695
J Acquir Immune Defic Syndr. 2012 May 1;60(1):e1-7
pubmed: 22240465
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
J Int AIDS Soc. 2016 Jul 20;19(5 Suppl 4):20846
pubmed: 27443273
BMC Infect Dis. 2016 May 20;16:214
pubmed: 27198545
J Int AIDS Soc. 2021 Aug;24(8):e25775
pubmed: 34347366
PLoS One. 2019 May 6;14(5):e0215855
pubmed: 31059523
PLoS One. 2015 Jul 06;10(7):e0132053
pubmed: 26147473

Auteurs

Santiago Izco (S)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saude de Manhiça (CISM), Manhiça, Mozambique.

Adrià Murias-Closas (A)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.

Alexander M Jordan (AM)

Mycotic Diseases Branch, United States Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Gregory Greene (G)

Mycotic Diseases Branch, United States Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Nteruma Catorze (N)

Centro de Investigação em Saude de Manhiça (CISM), Manhiça, Mozambique.

Helio Chiconela (H)

National Tuberculosis Program, Manhiça, Mozambique.

Juan Ignacio Garcia (JI)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saude de Manhiça (CISM), Manhiça, Mozambique.
PhD Program in Methodology of Biomedical Research, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Alejandro Blanco-Arevalo (A)

Internal Medicine Department, Hospital Universitari de Bellvitge, Barcelona, Spain.

Anna Febrer (A)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.

Aina Casellas (A)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.

Belén Saavedra (B)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saude de Manhiça (CISM), Manhiça, Mozambique.

Tom Chiller (T)

Mycotic Diseases Branch, United States Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Tacilta Nhampossa (T)

Centro de Investigação em Saude de Manhiça (CISM), Manhiça, Mozambique.

Alberto Garcia-Basteiro (A)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saude de Manhiça (CISM), Manhiça, Mozambique.

Emilio Letang (E)

ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Department of Infectious Diseases Hospital del Mar, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH